TUMOR INFILTRATING LYMPHOCYTES
Clinical trials for TUMOR INFILTRATING LYMPHOCYTES explained in plain language.
Never miss a new study
Get alerted when new TUMOR INFILTRATING LYMPHOCYTES trials appear
Sign up with your email to follow new studies for TUMOR INFILTRATING LYMPHOCYTES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Supercharged immune cells take on tough pancreatic cancer
Disease control Recruiting nowThis early-phase trial tests a new therapy called GC203 TIL, which uses a patient's own immune cells that are genetically modified to better attack pancreatic cancer. Ten adults whose cancer has not responded to standard treatments will receive these cells after a short course of…
Matched conditions: TUMOR INFILTRATING LYMPHOCYTES
Phase: EARLY_PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Patient's own immune cells fight advanced cancer?
Disease control Recruiting nowThis trial investigates whether tumor-infiltrating lymphocytes (TILs) — immune cells taken from a patient's own tumor — can be expanded in the lab and infused back to attack cancer. It enrolls adults aged 18 to 75 with advanced solid tumors who have failed standard treatments. Th…
Matched conditions: TUMOR INFILTRATING LYMPHOCYTES
Phase: EARLY_PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could your own tumor cells fight cancer? new trial tests TIL therapy
Disease control Recruiting nowThis early-phase trial tests a personalized therapy where immune cells (TILs) are taken from a patient's own tumor, multiplied in a lab, and infused back into the body to attack the cancer. The study includes both natural and gene-edited TILs and enrolls 30 adults with advanced s…
Matched conditions: TUMOR INFILTRATING LYMPHOCYTES
Phase: EARLY_PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC